page_title: Serotonin–dopamine reuptake inhibitor
section_title: Research chemicals
hierarchical_section_title: Serotonin–dopamine reuptake inhibitor / Examples of SDRIs / Research chemicals
caption_attribution_description: English: Example of a SDRI Doi: 10.1016/j.bmcl.2010.10.086
context_page_description: A serotonin–dopamine reuptake inhibitor is a type of drug which acts as a reuptake inhibitor of the monoamine neurotransmitters serotonin and dopamine by blocking the actions of the serotonin transporter and dopamine transporter, respectively. This in turn leads to increased extracellular concentrations of serotonin and dopamine, and, therefore, an increase in serotonergic and dopaminergic neurotransmission.
  A closely related type of drug is a serotonin–dopamine releasing agent.
context_section_description: Two SDRIs that are known in research at present are RTI-83 and UWA-101, though other related compounds are also known. Based on its chemical structure, UWA-101 may actually also possess some activity as a releasing agent, and if so, unlike RTI-83, it would not be an SDRI in the purest sense and would also be an SDRA. Manning et al. presented two high-affinity MAT-ligands with good binding selectivity for SERT and DAT, namely the 4-indolyl and 1-naphthyl arylalkylamines ent-16b (Kᵢ 0.82, 3.8, 4840 nM for SERT, DAT, NET) and ent-13b respectively. AN-788 (NSD-788) is another SDRI, and has been under development for the treatment of depressive and anxiety disorders.
caption: Compound 16 according to Liming Shao:[20]
exif: {}